232 related articles for article (PubMed ID: 20975615)
21. Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program.
Ozaki T
Vaccine; 2013 Dec; 31(51):6155-60. PubMed ID: 24183712
[TBL] [Abstract][Full Text] [Related]
22. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
[TBL] [Abstract][Full Text] [Related]
23. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.
Mutsaerts EAML; Nunes MC; Bhikha S; Ikulinda BT; Jose L; Koen A; Moultrie A; Grobbee DE; Klipstein-Grobusch K; Weinberg A; Madhi SA
Vaccine; 2020 May; 38(22):3862-3868. PubMed ID: 32307279
[TBL] [Abstract][Full Text] [Related]
24. A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission.
Gershon AA; Steinberg S; Gelb L; Galasso G; Borkowsky W; LaRussa P; Ferrara A
Postgrad Med J; 1985; 61 Suppl 4():73-8. PubMed ID: 3014482
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of children with malignant disease against varicella.
Slørdahl SH; Wiger D; Strømøy T; Degre M; Thørsby E; Lie SO
Postgrad Med J; 1985; 61 Suppl 4():85-92. PubMed ID: 3014484
[TBL] [Abstract][Full Text] [Related]
26. Live attenuated varicella virus vaccine. Efficacy trial in healthy children.
Weibel RE; Neff BJ; Kuter BJ; Guess HA; Rothenberger CA; Fitzgerald AJ; Connor KA; McLean AA; Hilleman MR; Buynak EB
N Engl J Med; 1984 May; 310(22):1409-15. PubMed ID: 6325909
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.
Ramkissoon A; Coovadia HM; Jugnundan P; Haffejee IE; Meurice F; Vandevoorde D
S Afr Med J; 1995 Dec; 85(12):1295-8. PubMed ID: 8600589
[TBL] [Abstract][Full Text] [Related]
28. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers.
Saiman L; LaRussa P; Steinberg SP; Zhou J; Baron K; Whittier S; Della-Latta P; Gershon AA
Infect Control Hosp Epidemiol; 2001 May; 22(5):279-83. PubMed ID: 11428437
[TBL] [Abstract][Full Text] [Related]
29. [Safety and immunogenicity of lyophilized live attenuated domestic varicella vaccine].
Chen EF; Jiang ZG; Li Q
Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):435-7. PubMed ID: 20084971
[TBL] [Abstract][Full Text] [Related]
30. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine.
Bernstein HH; Rothstein EP; Watson BM; Reisinger KS; Blatter MM; Wellman CO; Chartrand SA; Cho I; Ngai A; White CJ
Pediatrics; 1993 Dec; 92(6):833-7. PubMed ID: 8233746
[TBL] [Abstract][Full Text] [Related]
31. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine.
Gershon AA; Steinberg SP
N Engl J Med; 1989 Apr; 320(14):892-7. PubMed ID: 2538749
[TBL] [Abstract][Full Text] [Related]
32. Safety and Immunogenicity of the Live Attenuated Varicella Vaccine in Vietnamese Children Aged 12 Months to 12 Years: An Open-Label, Single-Arm Bridging Study.
Hung PV; Giang LTH; Toi PL; Thuc VTM; Anh BDT; Pho DC; Hung PN
Viruses; 2024 May; 16(6):. PubMed ID: 38932134
[TBL] [Abstract][Full Text] [Related]
33. Persistence of immunity to live attenuated varicella vaccine in healthy adults.
Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A
Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.
Chaves Tdo S; Lopes MH; de Souza VA; Dos Santos Sde S; Pereira LM; Reis AD; David-Neto E
Pediatr Transplant; 2005 Apr; 9(2):192-6. PubMed ID: 15787792
[TBL] [Abstract][Full Text] [Related]
36. Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years.
Hadinegoro SR; Hindra IS; Han HH; Gatchalian S; Bock HL
Southeast Asian J Trop Med Public Health; 2009 Sep; 40(5):991-9. PubMed ID: 19842382
[TBL] [Abstract][Full Text] [Related]
37. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings.
Diaz PS; Au D; Smith S; Amylon M; Link M; Smith S; Arvin AM
Pediatrics; 1991 Feb; 87(2):166-70. PubMed ID: 1846236
[TBL] [Abstract][Full Text] [Related]
38. [Investigation on sera prevalence rate of varicella and immunogenicity of varicella vaccine in healthy children].
Zhou T; Wang J; Qiu P
Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Oct; 19(5):271-3. PubMed ID: 10322684
[TBL] [Abstract][Full Text] [Related]
39. Live attenuated varicella vaccine: the KMcC strain in healthy children.
Arbeter AM; Starr SE; Weibel RE; Neff BJ; Plotkin SA
Pediatrics; 1983 Mar; 71(3):307-12. PubMed ID: 6298698
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan.
Ozaki T; Nishimura N; Muto T; Sugata K; Kawabe S; Goto K; Koyama K; Fujita H; Takahashi Y; Akiyama M
Vaccine; 2005 Jan; 23(10):1205-8. PubMed ID: 15652662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
